The alteration of Hippo/YAP signaling in the development of hypertrophic cardiomyopathy
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Hypertrophic cardiomyopathy (HCM) is a leading cause of heart failure and sudden death in adolescents and young adults. Recently, the role of the Hippo/YAP pathway has been investigated in the pathogenesis of HCM, although the detailed molecular mechanisms largely remain elusive. In this study, we demonstrated an up-regulation of YAP mRNA and protein levels in both HCM patient samples and transverse aortic constriction murine models as well as reduced phosphorylation of YAP at serine 127 accompanied by increased transcription of YAP-mediated genes in hypertrophic heart tissues. The cardiomyocyte-specific transgene of human YAP induced cardiac hypertrophy and increased fetal gene expression in the heart. In primary cultured murine cardiomyocytes, ectopic expression of YAP resulted in increased cellular size, whereas the knockdown of YAP reduced the cell size induced by phenylephrine treatment. Interestingly, both mRNA and protein levels of MST1, the kinase upstream of YAP, were dramatically decreased. Further experiments showed that transcription factor FOXO3 binds to the MST1 promoter and that the PI3 K/Akt/FOXO3 signaling pathway regulates MST1 expression. Our findings define the alteration of the Hippo/YAP pathway in the development of HCM. The exploitation of this pathway may provide a novel therapeutic avenue for this disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, Yap is activated in hearts stressed by pathological pressure overload (144) and in the area bordering a myocardial infarction in mice (25).”
From The Hippo signal transduction network for exercise physiologists (2016) · cites this paper as [144]
In the citing paper
“Yap is expressed at higher levels and dephosphorylated (activated) in samples obtained from pathologically hypertrophied human hearts (144).”
From The Hippo signal transduction network for exercise physiologists (2016) · cites this paper as [144]
Citations
Cites
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Molkentin, J. D., Lu, J.-R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566 · cited 1×
“Other downstream mediators of hypertrophy include CaM kinase II [1, 2, 35], calcineurin [25, 27, 32], NFAT [21, 26], and protein kinases C and D [14, 19, 36] as well as members of the MAPK family [18, 20] and the PI3 K-Akt pathway [6, 31].”
BackgroundTEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal
Zhao, B., Tumaneng, K., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2303 · Cited by 1,205 · cited 1×
“The Hippo/MST signaling pathway, first identified in Drosophila, has been delineated as an organ size control pathway [29, 40].”
BackgroundHippo Pathway Inhibits Wnt Signaling to Restrain Cardiomyocyte Proliferation and Heart Size
Heallen, T., Zhang, M., Wang, J., Bonilla-Claudio, M., Klysik, E., Johnson, R. L., & Martin, J. F. (2011) · Science · doi:10.1126/science.1199010 · Cited by 1,092 · cited 1×
“Cardiomyocyte proliferation was shown to be elevated in both the left and right ventricles in the absence of Salvador [16].”
BackgroundZhou, D., Conrad, C., Xia, F., Park, J.-S., Payer, B., Yin, Y., Lauwers, G. Y., Thasler, W., Lee, J. T., Avruch, J., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.026 · Cited by 913 · cited 1×
“MST1 and MST2 are key components of the Hippo tumor suppressor pathway, and MST1/2 ablation or YAP overexpression leads to hepatocellular carcinomas [42].”
BackgroundChronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy
Takimoto, E., Champion, H. C., Li, M., Belardi, D., Ren, S., Rodriguez, E. R., Bedja, D., Gabrielson, K. L., Wang, Y., & Kass, D. A. (2005) · Nature Medicine · doi:10.1038/nm1175 · Cited by 903
Hippo signaling in organ size control
Pan, D. (2007) · Genes & Development · doi:10.1101/gad.1536007 · Cited by 647 · cited 1×
“The Hippo/MST signaling pathway, first identified in Drosophila, has been delineated as an organ size control pathway [29, 40].”
BackgroundRegulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways
Crackower, M. A., Oudit, G. Y., Kozieradzki, I., Sarao, R., Sun, H., Sasaki, T., Hirsch, E., Suzuki, A., Shioi, T., Irie-Sasaki, J., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00969-8 · Cited by 576
von Gise, A., Lin, Z., Schlegelmilch, K., Honor, L. B., Pan, G. M., Buck, J. N., Ma, Q., Ishiwata, T., Zhou, B., Camargo, F. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116136109 · Cited by 573
Vega, R. B., Harrison, B. C., Meadows, E., Roberts, C. R., Papst, P. J., Olson, E. N., & McKinsey, T. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8374-8385.2004 · Cited by 511
Research works printed but not linked: 2
- Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson RL, Martin JF (2011) Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 332:458–461. doi: 10.1126/science.1199010 · DOI · Paper page
- von Gise A, Lin Z, Schlegelmilch K, Honor LB, Pan GM, Buck JN, Ma Q, Ishiwata T, Zhou B, Camargo FD, Pu WT (2011) YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. Proc Natl Acad Sci USA 109:2394–2399. doi: 10.1073/pnas.1116136109 · DOI · Paper page
Cited by
Mechanisms of physiological and pathological cardiac hypertrophy
Nakamura, M., & Sadoshima, J. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0007-y · Cited by 1,658
The Hippo signalling pathway and its implications in human health and diseases
Fu, M., Hu, Y., Lan, T., Guan, K.-L., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 742
“298 However, the condition seems to be different in ARCV 299 and DCM, 300 in which the Hippo pathway was activated, leading to YAP inactivation.”
BackgroundThe Hippo pathway in the heart: pivotal roles in development, disease, and regeneration
Wang, J., Liu, S., Heallen, T., & Martin, J. F. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0063-3 · Cited by 380
The Hippo Pathway in Heart Development, Regeneration, and Diseases
Zhou, Q., Li, L., Zhao, B., & Guan, K.-L. (2015) · Circulation Research · doi:10.1161/circresaha.116.303311 · Cited by 219
Ikeda, S., Mizushima, W., Sciarretta, S., Abdellatif, M., Zhai, P., Mukai, R., Fefelova, N., Oka, S., Nakamura, M., Re, D. P. D., et al. (2019) · Circulation Research · doi:10.1161/circresaha.118.314048 · Cited by 130
Common Regulatory Pathways Mediate Activity of MicroRNAs Inducing Cardiomyocyte Proliferation
Torrini, C., Cubero, R. J., Dirkx, E., Braga, L., Ali, H., Prosdocimo, G., Gutiérrez, M. I., Collesi, C., Licastro, D., Zentilin, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.005 · Cited by 119
The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications
Wang, X., Chen, L., Wei, J., Zheng, H., Zhou, N., Xu, X., Deng, X., Liu, T., & Zou, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02220-z · Cited by 148
“489,492 Furthermore, activation of YAP in tissue samples from hypertrophic cardiomyopathy and in TAC-induced failing hearts from mice, suggesting that the Hippo/YAP signaling pathway plays a role in the development of cardiac hypertrophy and HF. 493 Cardiomyocyte-speci fi c inhibition of MST1 reduced neutrophil and mac…”
Li, L.-S., Fang, R., Liu, B., Shi, H., Wang, Y., Zhang, W., Zhang, X., & Ye, L. (2015) · Oncogene · doi:10.1038/onc.2015.476 · Cited by 94
The Hippo Signaling Pathway in Cardiac Development and Diseases
Mia, M. M., & Singh, M. K. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00211 · Cited by 92
FOXOs in the impaired heart: New therapeutic targets for cardiac diseases
Xin, Z., Ma, Z., Jiang, S., Wang, D., Fan, C., Di, S., Hu, W., Li, T. X., She, J., & Yang, Y. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.11.023 · Cited by 87
Regulation of Myocardial Cell Growth and Death by the Hippo Pathway
Ikeda, S., & Sadoshima, J. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0476 · Cited by 63
Pfleger, C. M. (2017) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2016.12.001 · Cited by 67
Yue, P., Zhang, Y., Liu, L., Zhou, K., Xia, S., Peng, M., Yan, H., Tang, X., Chen, Z., Zhang, D., et al. (2022) · Theranostics · doi:10.7150/thno.74563 · Cited by 65
“For example, animal studies have shown that YAP1 overexpression and hyperactivation in the heart can trigger ventricular wall thickening, cardiac pathogenesis, and even death [13, 14].”
BackgroundActivation of Yap1/Taz signaling in ischemic heart disease and dilated cardiomyopathy
Hou, N., Wen, Y., Yuan, X., Xu, H., Wang, X., Li, F., & Ye, B. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.11.006 · Cited by 61
Yu, Y., Su, X., Qin, Q., Hou, Y., Zhang, X., Zhang, H., Jia, M., & Chen, Y. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105009 · Cited by 63
Hippo signaling in stress response and homeostasis maintenance
Mao, B., Gao, Y., Bai, Y., & Yuan, Z. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmu109 · Cited by 57
“[56] found that cardiomyocyte-specific transgene of human YAP induced cardiac hypertrophy and increased fetal gene expression in the heart of 3 months old mice.”
BackgroundSelf-citationTargeting the Hippo pathway in heart repair
Meng, F., Xie, B., & Martin, J. F. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab291 · Cited by 56
The Hippo signal transduction network for exercise physiologists
Gabriel, B. M., Hamilton, D. L., Tremblay, A. M., & Wackerhage, H. (2016) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01076.2015 · Cited by 48
Melatonin attenuates doxorubicin‐induced cardiotoxicity through preservation of YAP expression
Li, H., Wang, C., Sun, P., Liu, D., Du, G., & Tian, J. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15057 · Cited by 47
Self-citationThe Hippo-YAP pathway in various cardiovascular diseases: Focusing on the inflammatory response
Zheng, A., Chen, Q., & Zhang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.971416 · Cited by 58
“Molecular biology experiments showed that YAP is highly expressed and activated in hypertrophic cardiomyopathy tissue samples, as well as in TAC murine hearts, indicating that Hippo/ YAP signaling is involved in the pathogenesis of cardiac hypertrophy (118) (Table 2; Figure 3).”
BackgroundLncRNA MALAT1 regulates diabetic cardiac fibroblasts through the Hippo–YAP signaling pathway
Liu, J., Xu, L. Z., & Zhan, X. (2020) · Biochemistry and Cell Biology · doi:10.1139/bcb-2019-0434 · Cited by 45
“YAP is highly expressed and activated in hypertrophic cardiomyopathy tissue samples, and alteration of the Hippo/YAP pathway is pivotal in the development of hypertrophic cardiomyopathy (Wang et al. 2014).”
BackgroundRetractedIslam, R. M., & Hong, Z. (2024) · Mechanobiology in Medicine · doi:10.1016/j.mbm.2024.100085 · Cited by 50
“11 Additionally, in pulmonary arterial hypertension, YAP has demonstrated bene fi cial effects by inhibiting the proliferation of pulmonary smooth muscle cells (PASMCs) stimulated by Galectin-3.”
Ma, L., Yang, F., Wu, X. Y., Mao, C., Guo, L., Miao, T., Zang, S., Jiang, X., Shen, D., Wei, T., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2117054119 · Cited by 37
Hippo-Yap Signaling Maintains Sinoatrial Node Homeostasis
Zheng, M., Li, G., Song, J., Zhao, X., Tang, L., Erhardt, S., Chen, W., Nguyen, B. H., Li, X., Li, M., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.058777 · Cited by 37
Veltrop, R. J. A., Kukk, M. M., Topouzidou, K., Didden, L., Muchir, A., van Steenbeek, F. G., Schurgers, L. J., & Harakaľová, M. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01546-5 · Cited by 36
“…phosphorylation is down-regulated in HCM [61], indicating that MST1-mediated autophagy inhibition is higher in DCM. Lending support to this, MST1 expression is down-regulated in HCM via PI3K/AKT1-medi-ated forkhead box O3 (FOXO3) inhibition [55], leading to increased YAP1 activation.”
BackgroundInfluentialForce-sensing protein expression in response to cardiovascular mechanotransduction
Wang, Y.-T., Chatterjee, E., Li, G., Xu, J., & Xiao, J. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105412 · Cited by 43
Understanding the role of mammalian sterile 20-like kinase 1 (MST1) in cardiovascular disorders
Yang, Y., Wang, H., Ma, Z., Hu, W., & Sun, D. (2017) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2017.11.010 · Cited by 34
Untangling the role of RhoA in the heart: protective effect and mechanism
Miyamoto, S. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06928-8 · Cited by 37
“YAP activity is increased in the mouse heart in response to TAC as well as in human hypertrophic cardiomyopathy [35, 92] and this response has been suggested to be mediated by RhoA [35].”
BackgroundZhang, Z., Zhang, T., Zhou, Y., Wei, X., Zhu, J., Zhang, J., & Wang, C. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373978 · Cited by 31
Zheng, M., Jacob, J., Hung, S.-H., & Wang, J. (2020) · Biomolecules · doi:10.3390/biom10071024 · Cited by 31
Amanda, B., Pragasta, R., Cakrasana, H., Mustika, A., Faizah, Z., & Oceandy, D. (2024) · Cells · doi:10.3390/cells13221868 · Cited by 28
Jiang, W., Ren, W.-H., Liu, X., Liu, Y., Wu, F., Sun, L., Lan, F., Du, J., & Zhang, H. (2016) · Aging · doi:10.18632/aging.101033 · Cited by 30
“Our previous study found that enlargement of cardio-myocytes, which is induced by YAP up-regulation, led to cardiac hypertrophy [22].”
Self-citationLumish, H. S., Sherrid, M. V., Janssen, P. M. L., Ferrari, G. M., Hasegawa, K., Castillero, E., Adlestein, E., Swistel, D. G., Topkara, V. K., Maurer, M. S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.043 · Cited by 28
Sharifi‐Sanjani, M., Berman, M., Goncharov, D. A., Alhamaydeh, M., Avolio, T., Baust, J., Chang, B., Kobir, A., Ross, M., Croix, C. M. S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116164 · Cited by 28
“Yap and its upstream negative regulator HIPPO are confirmed modulators of cardiomyocyte growth and survival [46,47] while HIPPO signaling deficiency prevents cardiac fibroblast differentiation during heart development via Yap [48].”
BackgroundMondal, A., Das, S., Samanta, J., Chakraborty, S., & Sengupta, A. (2022) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2022.109198 · Cited by 29
SLIT3 deficiency attenuates pressure overload–induced cardiac fibrosis and remodeling
Gong, L., Wang, S., Shen, L., Liu, C., Shenouda, M., Li, B., Liu, X., Shaw, J. A., Wineman, A. S., Yang, Y., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.136852 · Cited by 25
“We found that the transcript levels of Yap1, rather than Taz, and its 243 regulated gene Ctgf in the cardiac ventricles after TAC were reduced significantly in Slit3-/- compared with 244 WT mice (Figure 7C and Supplemental Figure 6B) (61).”
ResultXiong, J., Dong, X., Li, S., Jiang, F., Chen, J., Yu, S., Dong, B., & Su, Q. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.657378 · Cited by 24
Protein kinases in cardiovascular diseases
Chen, J., Li, Y., Du, C., Wei, T., Shan, T., & Wang, L. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001870 · Cited by 26
“function↓ Phosphorylates FOXO3 to upregulate YAP expression [83]”
BackgroundRNA-seq profiling of mRNA associated with hypertrophic cardiomyopathy
Ren, C., Liu, J., Li, J., Li, J., Dai, J., & Lai, Y. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5931 · Cited by 26
“HCM is a common cause of sudden cardiac arrest in young people, including young athletes (5,6).”
Self-citationLi, H., Jiang, W., Ren, W., Guo, D., Guo, J., Wang, X., Liu, Y., Lan, F., Du, J., & Zhang, H. (2016) · Stem Cells International · doi:10.1155/2016/6786184 · Cited by 23
“According to our previous study, YAP plays a key role in hypertrophic cardiomyopathy [11].”
BackgroundSelf-citationGlycyrrhizic acid alleviated MI/R-induced injuries by inhibiting Hippo/YAP signaling pathways
Cheng, X. W., Liu, Y., Qi, B., Wang, Y., Zheng, Y., Liang, X., Chang, Y., Ning, M., Gao, W., & Li, T. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111036 · Cited by 24
Hu, X., Shen, G., Lü, X., Ding, G., & Shen, L. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.75593 · Cited by 20
“Moreover, the Hippo/YAP pathway was found to be activated in HCM [7].”
BackgroundHippo and Cardiac Hypertrophy: A Complex Interaction
Windmueller, R., & Morrisey, E. E. (2015) · Circulation Research · doi:10.1161/circresaha.115.307546 · Cited by 17
Hippo signaling in cardiac fibroblasts during development, tissue repair, and fibrosis
Tsai, C.-R., & Martin, J. F. (2022) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2022.02.010 · Cited by 15
A positive feedback regulation of Heme oxygenase 1 by CELF1 in cardiac myoblast cells
Liu, Y., Wang, H., Wang, J., Wei, B. K., Zhang, X., Zhang, M., Cao, D., Dai, J., Wang, Z., Nyirimigabo, E., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2018.11.006 · Cited by 14
Self-citationFan, M., Song, J., He, Y., Shen, X., Li, J., Que, L., Zhu, G., Zhu, Q., Cai, X., Ha, T., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.03.002 · Cited by 13
“In addition, the up-regulated expression of YAP has been shown in both heart samples of dilated cardiomyopathy patients and transverse aortic constriction (TAC)-induced animal models [20].”
BackgroundAhmed, D. W., Eiken, M. K., DePalma, S. J., Helms, A. S., Zemans, R. L., Spence, J. R., Baker, B. M., & Loebel, C. (2023) · iScience · doi:10.1016/j.isci.2023.108472 · Cited by 11
“84 In addition to YAP/TAZ, mechanical signals are transmitted through Piezo1-dependent Ca 2+ influx and ATP release.”
BackgroundCardiac Fibroblasts: Helping or Hurting
Shameem, M., Olson, S. L., de Velasco, E. M. F., Kumar, A., & Singh, B. N. (2025) · Genes · doi:10.3390/genes16040381 · Cited by 16
“Dysregulation of the Hippo pathway leads to cardiac diseases like cardiomyopathy, heart failure, coronary heart diseases, and myocardial infarction [108,109].”
Multiscale mapping of transcriptomic signatures for cardiotoxic drugs
Hansen, J., Xiong, Y., Siddiq, M. M., Dhanan, P., Hu, B., Shewale, B., Yadaw, A. S., Jayaraman, G., Tolentino, R. E., Chen, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52145-4 · Cited by 16
Role of the HIPPO pathway as potential key player in the cross talk between oncology and cardiology
Manno, G., Filorizzo, C., Fanale, D., Brando, C., Lisi, D. D., Lunetta, M., Bazan, V., Russo, A. D., & Novo, G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103246 · Cited by 11
Depletion of VGLL4 Causes Perinatal Lethality without Affecting Myocardial Development
Sheldon, C., Farley, A., Ma, Q., Pu, W. T., & Lin, Z. (2022) · Cells · doi:10.3390/cells11182832 · Cited by 8
“Notably, all our studies were carried out in unstressed mice, and it remains unknown whether VGLL4 has significant pathophysiological roles in disease-stressed hearts, in which the LATS1/2 suppression of YAP is attenuated, and the nuclei YAP is enriched [31,35].”
BackgroundSome Insights into the Regulation of Cardiac Physiology and Pathology by the Hippo Pathway
Ramaccini, D., Pedriali, G., Perrone, M., Bouhamida, E., Modesti, L., Wieckowski, M. R., Giorgi, C., Pinton, P., & Morciano, G. (2022) · Biomedicines · doi:10.3390/biomedicines10030726 · Cited by 9
Chen, Q., Zhang, H., Chen, Y., Peng, Y., Yao, Y., Xue, H., Guo, Q., Tian, D., Xiao, L., Teng, X., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123554 · Cited by 11
The Roles of Signaling Pathways in Cardiac Regeneration
Valizadeh, A., Asghari, S., Mansouri, P., Alemi, F., Majidinia, M., Mahmoodpoor, A., & Yousefi, B. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210914115411 · Cited by 11
Langa, P., Marszalek, R. J., Warren, C. M., Chowdhury, S. A. K., Hałas, M., Batra, A., Rafael-Clyke, K., Bacon, A., Goldspink, P. H., Solaro, R. J., et al. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1136852 · Cited by 7
“Involvement of the Hippo pathway with YAP and TAZ as the primary sensors formechano-transduction signaling has been identified as a potentially significant mechano-sensing mechanism in septal human heart samples in late stage HCM and in pressure/overload hypertrophic growth with up and downregulation of Hippo signalin…”
BackgroundOkuyama, M., Jiang, W., Yang, L., & Subramanian, V. (2021) · Circulation Reports · doi:10.1253/circrep.cr-20-0104 · Cited by 7
Self-citationLanga, P., Shafaattalab, S., Goldspink, P. H., Wolska, B. M., Fernandes, A. A., Tibbits, G. F., & Solaro, R. J. (2023) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2022.0176 · Cited by 6
“Evidence for this speculation included reports of a role of HIPPO signalling in models of pressure overload stress in mice [11] and in late stages of human HCM and a DCMmouse model with desmin ablation [12,13], as well as modifications and associations of Notch signals in human DCM [14] and a DCM mouse model expressin…”
BackgroundRawson, R., Duong, L., Tkachenko, E., Chiang, A. W. T., Okamoto, K., Dohil, R., Lewis, N. E., Kurten, R. C., Abud, E. M., & Aceves, S. S. (2024) · Mucosal Immunology · doi:10.1016/j.mucimm.2024.02.007 · Cited by 6
“In cardiac and skeletal muscle, YAP is known to induce cell hypertrophy 18 .”
BackgroundRehmani, T., Mlynarova, J., Byers, J. T., Salih, M., & Tuana, B. S. (2021) · Cardiogenetics · doi:10.3390/cardiogenetics11040018 · Cited by 7
“Whether injury, such as myocardial infarction or pressure overload, would impact Hippo in SLMAP3 deficient hearts, and function remains to be investigated [51].”
BackgroundWang, J., Wang, Z., Xia, F., Duan, Q., & Peng, X. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.08.028 · Cited by 7
Zhang, Y., Ren, Y., Li, X., Li, M., Fu, M., Zhou, W., Yu, Y., & Xiong, Y. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132473 · Cited by 5
Wang, J., Jing, K., Mitrokhin, V. M., Shileiko, S. A., Rodina, A., Zolotareva, A., Zolotarev, V. I., Bocharnikova, N., Kaminer, D. D., Antova, E., et al. (2025) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-025-01099-2 · Cited by 5
“In this regard, inhibited YAP-Serine127 phos - phorylation was observed in both human and mouse cardiac tissues [31 ].”
InfluentialOral administration of MnCl2 attenuated hyperlipidemia-related cardiac remodeling in ApoE−− mice
Zhang, H.-X., Zhang, C.-S., Huang, R., Cao, X., Dai, X., Zuo, C.-Y., Lv, P., Zhu, L., & Yu, S. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.11.010 · Cited by 4
Li, Y., Zeng, Y., Lian, Y., Zhang, C., Chen, X., Zhang, S., Huang, Y., Yuan, W., Qin, Y., Liu, D., et al. (2026) · Diabetes · doi:10.2337/db25-0435 · Cited by 3
Self-citationDuursma, I., Micali, L. R., Nollet, E. E., Jansen, V., Malone, J. A., Bloem, J. S., Margulies, K. B., Margulies, K. B., Schoonvelde, S. A. C., Michels, M., et al. (2026) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2025.100655 · Cited by 4
TAZ Is Related to Postoperative In-Hospital Mortality of Acute Type A Aortic Dissection
Jiang, W., Xue, Y., Li, H., Zhang, H., & Zhao, Y. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.587996 · Cited by 3
“Our previous study found that Hippo pathway expression played a key role in hypertrophic cardiomyopathy (22).”
Self-citationAdenosine triphosphate-induced cell death in heart failure: Is there a link?
Zhang, J., Cheng, L., Qiao, Q., Xiao, X.-L., Lin, S., He, Y., Sha, R.-L., Sha, J., Ma, Y., Zhang, H.-L., et al. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i4.105021 · Cited by 3
“This study provides insights into how the dysregulation of signaling pathways can contribute to the pathogenesis of cardiomyopathy, potentially involving AICD signaling pathways[24].”
Sheng, S., Ding, L., Lai, J., Ye, Z., Zhao, R., Chen, S., Ma, J., Fan, J., & Jin, P. (2025) · Cardiovascular Therapeutics · doi:10.1155/cdr/2852780 · Cited by 1
“In vitro experiments with primary CMs from mice show that overexpression of YAP induces cell enlargement [23].”
Wang, F., Huang, M., Sheng, K., Yan, Y., Zhang, B., Wang, X., Yang, Z., Li, M., Liu, Y., Qi, Q., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03765-1 · Cited by 1
“Recent studies using multidimensional regulatory metabolic models have identi fi ed abnormalities in the Hippo signaling pathway as key drivers of HCC [38].”
Self-citationGenome Editing and Cardiac Regeneration
Bassawon, R., Khan, K., Siddique, A., & Shum‐Tim, D. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_3 · Cited by 1
Chirikian, O., Faynus, M. A., Merk, M. W., Singh, Z., Muray, C., Pham, J., Chialastri, A., Roest, A. S. V., Goldstein, A. J., Pyle, T., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.03.597045 · Cited by 3
“These studies indicate reduced levels of phosphorylated YAP (i.e. activated YAP with increased nuclear localization) and elevated levels of the well-established YAP downstream transcriptional target, Cellular Communication Network Factor 2 (CCN2) 31 .”
InfluentialVastrad, B. M., Pattanashetti, S., & Vastrad, C. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.13.618070 · Cited by 1
Identification of Core Gene Biomarkers in Patients With Hypertrophic CardiomyopathyPreprint
Yang, X., & Jiang, H. (2021) · Research Square · doi:10.21203/rs.3.rs-154667/v1
He, X., Wang, J., Xue, Y., Wang, S., Dong, Y., Zhang, H., & Wang, M. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03144-8 · Cited by 1
“In addition, YAP activation stimulated the proliferation of cardiomyocytes [25, 26].”
BackgroundHe, X., Wang, J., Xue, Y., Wang, S., Dong, Y., Zhang, H., & Wang, M. (2024) · Figshare · doi:10.6084/m9.figshare.26581439
Strip1 Is a Novel Negative Regulator of Cardiomyocyte Hypertrophy
Heilein, E., Kilian, L. S., Sossalla, S. T., Meder, B., Völkers, M., Frese, K., Herch, S., Frey, N., & Eden, M. (2026) · Cells · doi:10.3390/cells15060540 · Cited by 1
“In patients with hypertrophic cardiomyopathy (HCM), YAP activity and gene expression are elevated [51], consistent with findings in NRVCMs where YAP1 overexpression promotes and knockdown attenuates hypertrophy [52].”
Modulation of hippo pathway by alternative splicing
Srivastava, D. (2019) · theses.fr (ABES) · doi:10.70675/39639c36z8ae3z4f14z9907zaaead2a13436
“Similarly, in 2014 (Sorrentino et al., 2014) and (Z. Wang et al., 2014) described how statin (a class of drug to treat hypercholesterolemia) indirectly inhibit YAP and TAZ by reducing the downstream synthesis of geranylgeranyl pyrophosphate, which is required for Rho GTPases to inhibit LATS kinase…”
BackgroundBlandin, C. (2023) · theses.fr (ABES) · doi:10.70675/bedafc9ez5195z4b52z913bz548743c18b89
Tissue remodeling in eosinophilic esophagitis
Aceves, S. S., Manresa, M. C., Dellon, E. S., Rieder, F., Collins, M. H., Lucendo, A. J., & Rothenberg, M. E. (2026) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2026.06.004
Hao, Y., Wu, Y. X., Zhang, X., Zhang, L., Zhang, Y., Cheng, Y., Wang, J., Ye, H., Duan, S., & Liu, H. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102351
Evidence for a role of adverse sarcomere signaling in atrial fibrillation induction
McCauley, M. D., & Solaro, R. J. (2026) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2026.100866
“Reactivation of both Notch signaling and Hippo signaling has been implicated in HCM, DCM and AF [168,173,180,182].”
Hao, Y., Zhang, X., Zhang, L., Zhang, Y., Wang, X., Cheng, Y., Wang, J., Ye, H., Duan, S., Liu, H., et al. (2026) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2026177
Kiyohara, Y., Akita, K., Fifer, M. A., Tower-Rader, A. F., Teruya, S. L., Ansari, B. A., Santos, A. M., Maurer, M. S., & Shimada, Y. J. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103470
Metadata
- Authors
- Wang, P., Mao, B., Luo, W., Wei, B., Jiang, W., Liu, D., Song, L., Ji, G., Yang, Z., Lai, Y.-Q., & Yuan, Z.
- Affiliations
- Capital Medical University (CN)
- Chinese Academy of Sciences (CN)
- Model Animal Research Center (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Yang, Zhongzhou
- Yuan, Zengqiang
- ORCID
- Venue
- Basic Research in Cardiology
- Published
- 2014-08-29
- Volume
- 109
- Issue
- 5
- Pages
- 435-435
- ISSN
- 0003-9217 (ISSN-L)
- 0300-8428
- 1435-1803
- OpenAlex
- W1969614725
- Cited by
- 83
- References
- 41
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 13 · 2023: 6 · 2022: 11 · 2021: 8 · 2020: 7 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 7 · 2015: 4 · 2014: 1
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Basic Research in Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Family Process Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- hypertrophic cardiomyopathy, Hippo/YAP signaling, YAP phosphorylation, MST1, FOXO3, PI3K/Akt signaling, cardiac hypertrophy, transverse aortic constriction, cardiomyocyte size, fetal gene expression, therapeutic target
- MeSH terms
- Hippo Signaling Pathway, YAP-Signaling Proteins, Adult, Aged, Animals, Cardiomyopathy, Hypertrophic, Female, Fluorescent Antibody Technique, Humans, Male, Mice, Inbred C57BL, Middle Aged, Phosphoproteins, Signal Transduction, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Chromatin Immunoprecipitation, Adaptor Proteins, Signal Transducing, Mice, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.